Avance (2021a).NPV vs rNPV.可查阅：https://avance.ch/download/npv-vs-rnpv/。
Avance (2021b).Discount rates in drug development.可查阅：https://avance.ch/download/discount-rates-in-pharma-and-biotech/。
Biotechnology Innovation Organization (2021).Clinical development success rates and contributing factors 2011–2020.Informa Pharma Intelligence, QLS advisors.
Black, F. and M. Scholes (1973).The Pricing of Options and Corporate Liabilities.Journal of Political Economy, 81(3), 637–654. http://www.jstor.org/stable/1831029.
Bogdan, B. and R. Villiger (2010).Valuation in Life Sciences0.3rd edn.Berlin, Heidelberg: Springer.
Chance, D.M. and P.P. Peterson (2002).Real Options and Investment Valuation.The Research Foundation of the Association for Investment Management and Research (now Chartered Financial Analyst Institute).
Clinical Research (2019).Cost of Clinical Trials: A Breakdown (Infographic).可查阅：www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trials-breakdown。
Cook, A.(2016).Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them.0.2nd edn.London: Gower.
Copeland, T. and V. Antikarov (2001).Real Options – A Practitioners’ Guide.New York: Texere.
Schlander, M. et al.(2021).How Much Does It Cost to Research and Develop a New Drug?A Systematic Review and Assessment.PharmacoEconomics, 39(11), pp. 1243–1269. doi.org/10.1007/s40273-021-01065-y.